Market Scope

Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis

Choose Your Experience

Over 500 Clients, Large & Small from Around the World, Have Trusted Market Scope Data & Analysis

Latest Market Reports

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.

Latest Industry News & Trends

3/7/2025
BreakingRegulationRetina
US FDA Approves Neurotech’s Cell Therapy Implant for MacTel
US FDA Approves Neurotech’s Cell Therapy Implant for MacTel

Neurotech Pharmaceuticals announced March 6 that the US FDA had approved Encelto, an encapsulated cell therapy implant to treat macular telangiectasia (MacTel) type 2. It’s the first FDA-approved t...

3/7/2025
BreakingCataractDry EyeFLACSGlaucomaMIGSOcular CancerRetinaRevenueSurgical
2024 Ophthalmic Revenue Roundup for Apellis, Immunocore, Sight Sciences, Ocular Therapeutix, Lensar, and ANI
2024 Ophthalmic Revenue Roundup for Apellis, Immunocore, Sight Sciences, Ocular Therapeutix, Lensar, and ANI

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported Feb. 28 that its 2024 net product revenue for Syfovre was $611.8 million, a 122.3 percent increase over $275.2 million in 2023. The comp...

3/7/2025
BreakingDry EyeGlaucoma
MediPrint Ophthalmics Adds HA-Eluting Contact Lens to Pipeline
MediPrint Ophthalmics Adds HA-Eluting Contact Lens to Pipeline

MediPrint Ophthalmics announced March 5 that it would expand its clinical program to address contact lens dropout due to discomfort with a drug-eluting contact lens that continuously delivers hyalu...

3/7/2025
BreakingRegulationRetina
Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)
Outlook Resubmits BLA to US FDA for Ophthalmic Bevacizumab (Lytenava)

Outlook Therapeutics reported Feb. 28 that it had resubmitted its biologics license application (BLA) to the US FDA for ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet age-rel...

3/7/2025
AllergyBreakingRegulationRetina
US FDA Approves ANI Pharmaceuticals’ Cortrophin Gel in Prefilled Syringe
US FDA Approves ANI Pharmaceuticals’ Cortrophin Gel in Prefilled Syringe

ANI Pharmaceuticals announced March 3 that the US FDA had approved a prefilled syringe of its purified Cortrophin gel. Among its many indications, the treatment targets acute and chronic inflammato...

3/7/2025
BreakingGene TherapyRegulationRetina
Avirmax Initiates IND-Enabling Studies of Dry AMD Triple-Gene Therapy Candidate
Avirmax Initiates IND-Enabling Studies of Dry AMD Triple-Gene Therapy Candidate

Avirmax Biopharma announced Feb. 28 that it had begun investigational new drug (IND) enabling studies of ABI-201, a viral vector that delivers three genes with the goal of preventing retinal pathog...

3/7/2025
BreakingRegulationThyroid Eye Disease
Japanese Regulators Grant Orphan Drug Status to HanAll’s Batoclimab in Active Thyroid Eye Disease
Japanese Regulators Grant Orphan Drug Status to HanAll’s Batoclimab in Active Thyroid Eye Disease

South Korea’s HanAll Biopharma announced March 6 that Japanese regulators had granted orphan drug designation to batoclimab, a subcutaneous anti-FcRn treatment being developed for autoimmune diseas...

3/7/2025
BreakingEuropeGene TherapyRegulationRetina
Ocugen’s Gene Therapy Candidates for GA and Stargardt Gain Advanced Therapy Status in Europe
Ocugen’s Gene Therapy Candidates for GA and Stargardt Gain Advanced Therapy Status in Europe

Ocugen announced March 3 that European regulators had granted advanced therapy medicinal product status to OCU410 and OCU410ST, the company’s subretinal gene therapy candidates for geographic atrop...

Provider Surveys & Interviews

Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Table of Innovation

Choose Your Own Adventure

Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.

Safe, Secure & On Any Device

We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.

Pre-Qualified Invitations

We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.

Better Data = Better Decisions

A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.

Market Scope+ App Screen

Market Scope Methodology

A Multi-Step Approach for Accurate & Timely Data

Proprietary data

  • 20+ years of physician survey data
  • Disease models
  • Cultivated database of physicians, ASCs, and hospitals
  • Insight from our team of in-house industry experts

Public data

  • Attendance and participation at major, worldwide meetings
  • Public health systems and registries
  • Clinical study data
  • Analysis of company-published financial reports

Join Market Scope Today

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more

Register A Clinical Account

A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.

Select your country...